The drug ACITREN contains one active pharmaceutical ingredient (API):
Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Poland
This drug has been assigned below unique identifiers within the countries it is being marketed: